PubRank

Clyde E Hart

Author PubWeight™ 18.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother 2004 2.27
2 A human colorectal explant culture to evaluate topical microbicides for the prevention of HIV infection. J Infect Dis 2005 2.26
3 The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis 2002 1.67
4 Field experience in implementing ISO 15189 in Kisumu, Kenya. Am J Clin Pathol 2010 1.52
5 Mucosal innate immune factors in the female genital tract are associated with vaginal HIV-1 shedding independent of plasma viral load. AIDS Res Hum Retroviruses 2006 1.37
6 Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proc Natl Acad Sci U S A 2011 1.30
7 HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum. J Infect Dis 2011 1.15
8 Diversity, divergence, and evolution of cell-free human immunodeficiency virus type 1 in vaginal secretions and blood of chronically infected women: associations with immune status. J Virol 2005 1.13
9 Carraguard Vaginal Gel Safety in HIV-Positive Women and Men in South Africa. J Acquir Immune Defic Syndr 2007 1.02
10 Detection of infectious human immunodeficiency virus type 1 in female genital secretions by a short-term culture method. J Clin Microbiol 2003 0.87
11 UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob Agents Chemother 2012 0.82
12 Female genital tract shedding of CXCR4-tropic HIV Type 1 is associated with a majority population of CXCR4-tropic HIV Type 1 in blood and declining CD4(+) cell counts. AIDS Res Hum Retroviruses 2012 0.78
13 Carrageenan-based gel retains limited anti-HIV-1 activity 8-24 hours after vaginal application by HIV-infected Thai women enrolled in a phase I safety trial. J Acquir Immune Defic Syndr 2012 0.77
14 Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women. AIDS 2010 0.77
15 Levels of intracellular phosphorylated tenofovir and emtricitabine correlate with natural substrate concentrations in peripheral blood mononuclear cells of persons prescribed daily oral TruvadaTM for HIV pre-exposure prophylaxis. J Acquir Immune Defic Syndr 2017 0.75